KRAS and neoplasm: Both in the in-house and the TCGA cohort, the level of the MeHEG score had no significant difference among several different clinical statuses, including the location of the tumor, KRAS/BRAF mutation status, and CpG island methylator phenotype (CIMP) status (Fig. 5a, b).